Non Small Cell Lung Cancer Clinical Trials in Chicago, Illinois

29 studies are recruiting for non small cell lung cancer in Chicago, Illinois right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations

   Global, Phase 3, randomized, multicenter, open-label study evaluating the efficacy and safety of firmonertinib at a dose level of 240 mg QD compared to investigator's choice of osimertinib (80 mg QD) or afatinib (40 mg QD) in participants who have locally advanced or metastatic NSCLC with EGFR PACC…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences Systems, Chicago, Illinois

   Locations

   141 in total

   Run by

   ArriVent BioPharma, Inc.

   See if you can join NCT07185997 on ClinicalTrials.gov

2. Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

   Beamion LUNG-3 study evaluates whether zongertinib, an oral HER2-targeted treatment, can improve outcomes compared with standard adjuvant treatment in adults with completely resected Stage II-IIIB non-small cell lung cancer (NSCLC) whose tumors have activating HER2 tyrosine kinase domain (TKD) muta…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences System, Chicago, Illinois

   Locations

   203 in total

   Run by

   Boehringer Ingelheim

   See if you can join NCT07195695 on ClinicalTrials.gov

3. Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers

   This is a phase 1/2, multicenter, open-label study. The phase 1 portion is a dose escalation and expansion study of STK-012 as monotherapy and in combination therapy in patients with selected advanced solid tumors. The phase 2 portion is a randomized study of STK-012 in combination with standard of…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   60 in total

   Run by

   Synthekine

   See if you can join NCT05098132 on ClinicalTrials.gov

4. Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]

   This is a phase 3 study of pembrolizumab in combination with carboplatin/taxane (paclitaxel or nab-paclitaxel) followed by pembrolizumab with or without maintenance sacituzumab tirumotecan (sac-TMT; MK-2870) in first-line treatment of metastatic squamous non-small cell lung cancer. It is hypothesiz…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   University of Chicago Medical Center ( Site 0145), Chicago, Illinois

   Locations

   217 in total

   Run by

   Merck Sharp & Dohme LLC

   See if you can join NCT06422143 on ClinicalTrials.gov

5. A Global Phase III Study of Rilvegostomig or Pembrolizumab Plus Chemotherapy for First-Line Treatment of Locally Advanced or Metastatic Squamous Non-small Cell Lung Cancer (NSCLC)

   The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell lung cancer (mNSCLC) whose tumors express programmed death-l…

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Research Site, Chicago, Illinois

   Locations

   333 in total

   Run by

   AstraZeneca

   See if you can join NCT06692738 on ClinicalTrials.gov

6. Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)

   The purpose of this study is to evaluate izalontamab brengitecan (iza-bren) combined with osimertinib in participants with previously untreated, locally advanced or metastatic EGFR-mutant NSCLC, compared to osimertinib alone or osimertinib combined with platinum-based chemotherapy

   Stage

   Phase 3

   Ages

   18 and older

   Site

   Local Institution - 0185, Chicago, Illinois

   Locations

   204 in total

   Run by

   Bristol-Myers Squibb

   See if you can join NCT07680790 on ClinicalTrials.gov

7. A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Non-Small Cell Lung Cancer

   This study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Non-Small Cell Lung Cancer

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Chicago, Chicago, Illinois

   Locations

   24 in total

   Run by

   Verastem, Inc.

   See if you can join NCT07659782 on ClinicalTrials.gov

8. A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

   The purpose of this study is to find out whether the study drug, LY4052031, is safe, tolerable and effective in participants with advanced, or metastatic solid tumors including urothelial cancer. The study is conducted in two parts - phase Ia (dose-escalation, dose-optimization) and phase Ib (dose-…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Chicago Hospital, Chicago, Illinois

   Locations

   39 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06465069 on ClinicalTrials.gov

9. A Study to Assess Adverse Events and How Intravenously (IV) Infused Telisotuzumab Vedotin (ABBV-399) Moves Through the Body as a Monotherapy in Adult Participants With Previously Treated Non-Squamous Non-Small Cell Lung Cancer (NSCLC)

   Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. The purpose of this study is to assess how safe telisotuzumab vedotin is in adult par…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   University of Illinois Hospital and Health Sciences System /ID# 275345, Chicago, Illinois

   Locations

   83 in total

   Run by

   AbbVie

   See if you can join NCT06568939 on ClinicalTrials.gov

10. A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

    This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung Cancer (NSCLC), and sarilumab, to evaluate to see if it can help with immune-related side effects from ubamatamab. The study is looking at: * How well …

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rush University Medical Center, Chicago, Illinois

    Locations

    18 in total

    Run by

    Regeneron Pharmaceuticals

    See if you can join NCT07154290 on ClinicalTrials.gov

11. Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung Cancer

    The study is intended to assess the safety and efficacy of perioperative treatment with Durvalumab in combination with Oleclumab, Monalizumab, or AZD0171 and platinum doublet chemotherapy (CTX); or Volrustomig or Rilvegostomig in combination with CTX; or Datopotamab deruxtecan (Dato-DXd) in combina…

    Stage

    Phase 2

    Ages

    18 to 95

    Site

    Research Site, Chicago, Illinois

    Locations

    97 in total

    Run by

    AstraZeneca

    See if you can join NCT05061550 on ClinicalTrials.gov

12. Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

    This is a first in human study of TNG456 alone and in combination with abemaciclib in patients with advanced or metastatic solid tumors known to have an MTAP loss. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific solid tum…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern Memorial Hospital, Chicago, Illinois

    Locations

    15 in total

    Run by

    Tango Therapeutics, Inc.

    See if you can join NCT06810544 on ClinicalTrials.gov

13. A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC)

    This trial will evaluate the efficacy and safety of various therapies in participants with Stage IB, IIA, IIB, IIIA, or selected IIIB resectable and untreated NSCLC tumors that meet protocol-specified biomarker criteria.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    38 in total

    Run by

    Genentech, Inc.

    See if you can join NCT04302025 on ClinicalTrials.gov

14. Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

    A Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer after failure of EGFR TKI Therapy

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Rush University Medical Center, Chicago, Illinois

    Locations

    187 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT07100080 on ClinicalTrials.gov

15. Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

    This study is being done to find out if a new medicine called PF-08634404, when given with chemotherapy, works better than the present standard treatment (pembrolizumab with chemotherapy) for adults with a type of lung cancer called non-small cell lung cancer (NSCLC) that is either locally advanced…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Illinois Hospital and Health Sciences System (Outpatient Cancer Center), Chicago, Illinois

    Locations

    484 in total

    Run by

    Pfizer

    See if you can join NCT07222566 on ClinicalTrials.gov

16. Study of Daraxonrasib (RMC-6236) in Patients With RAS Mutated NSCLC (RASolve 301)

    The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to docetaxel.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    University of Illinois Cancer Center, Chicago, Illinois

    Locations

    158 in total

    Run by

    Revolution Medicines, Inc.

    See if you can join NCT06881784 on ClinicalTrials.gov

17. Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

    Phase I Study, a master protocol to investigate TCR-Engineered T cells recognizing KRAS mutations in adult subjects with Unresectable, Advanced, and/or Metastatic Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Research Site, Chicago, Illinois

    Locations

    18 in total

    Run by

    AstraZeneca

    See if you can join NCT06218914 on ClinicalTrials.gov

18. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

    The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University Feinberg School of Medicine, Chicago, Illinois

    Locations

    37 in total

    Run by

    SystImmune Inc.

    See if you can join NCT05983432 on ClinicalTrials.gov

19. Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

    Clinical study of ivonescimab for first-line treatment of metastatic NSCLC patients with high PD-L1. Evaluating overall survival and progression free survival.

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Clinical Study Site, Chicago, Illinois

    Locations

    285 in total

    Run by

    Summit Therapeutics

    See if you can join NCT06767514 on ClinicalTrials.gov

20. A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors

    This is an open-label, phase 1/1b study evaluating the safety, tolerability, pharmacokinetic (what the body does to the drug), pharmacodynamic (what the drug does to the body), and antitumor activity of CGT4255 in adult participants with advanced solid tumors with ERBB2 alterations or HER2 overexpr…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    15 in total

    Run by

    Cogent Biosciences, Inc.

    See if you can join NCT07361562 on ClinicalTrials.gov

21. Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

    This is a Phase 1, open-label, multicenter, study of the safety, tolerability, PK, PD, and anti-tumor activity of MRTX1719 patients with advanced, unresectable or metastatic solid tumor malignancy with homozygous deletion of the MTAP gene.

    Stage

    Phase 1

    Ages

    18 and older

    Site

    Local Institution - 124, Chicago, Illinois

    Locations

    25 in total

    Run by

    Bristol-Myers Squibb

    See if you can join NCT05245500 on ClinicalTrials.gov

22. Phase III, Open-label Study of First-line Osimertinib With or Without Datopotamab Deruxtecan for EGFRm Locally Advanced or Metastatic Non-small Cell Lung Cancer

    The purpose of this study is to evaluate efficacy and safety of osimertinib (tablet) in combination with Dato-DXd (i.v. infusion) compared with osimertinib (tablet) monotherapyas a first-line therapy in participants with locally advanced or metastatic EGFRm (Ex19del and/or L858R) NSCLC. Study detai…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Research Site, Chicago, Illinois

    Locations

    167 in total

    Run by

    AstraZeneca

    See if you can join NCT06350097 on ClinicalTrials.gov

23. Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

    This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizuma…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    The University of Chicago Medical Center, Chicago, Illinois

    Locations

    42 in total

    Run by

    Inhibrx Biosciences, Inc

    See if you can join NCT04198766 on ClinicalTrials.gov

24. Radiotherapy to Block Oligoprogression In Metastatic Non-Small-Cell Lung Cancer

    This study is being done to answer the following question: Can the chance of lung cancer growing or spreading be lowered by adding targeted radiotherapy to the usual combination of drugs? This study is being done to find out if this approach is better or worse than the usual approach for lung cance…

    Stage

    Phase 3

    Ages

    18 and older

    Site

    Northwestern University, Chicago, Illinois

    Locations

    75 in total

    Run by

    Canadian Cancer Trials Group

    See if you can join NCT06686771 on ClinicalTrials.gov

25. Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan

    Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-Small Cell Lung Cancer (NSCLC) is a solid tumor, a disease in which cancer cells form in the tissues of the lung. Head and Neck Squamous Cell Carcinoma (HNSCC) is a solid tumor, a disease in which ca…

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Illinois Hospital and Health Sciences System /ID# 251750, Chicago, Illinois

    Locations

    48 in total

    Run by

    AbbVie

    See if you can join NCT05005403 on ClinicalTrials.gov